Submit Deal

Announced

30 Oct 2025

Novo Nordisk to acquire Metsera for $9.1bn.

Synopsis

Novo Nordisk, a global healthcare company, offered to acquire Metsera, a clinical-stage biotechnology company, for $9.1bn.

Principals

target

METSERA

bidder

Novo Nordisk

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context

Sort

Seller Team (1)

whit bernard

CEO at METSERA

Manager

target

Deals

£ 10.56 B

Total Value

Bidder Team (11)

sina meyer

Investor Relations Manager at NOVO NORDISK

Manager

bidder

Deals

£ 20.86 B

Total Value

alex bruce

Investor Relations Manager at NOVO NORDISK

Manager

bidder

Deals

£ 10.43 B

Total Value

ambre brown morley

Vice President Global Media & Stakeholder Communication at NOVO NORDISK

Manager

bidder

Deals

£ 21.89 B

Total Value

liz skrbkova

Senior Director at NOVO NORDISK

Manager

bidder

Deals

£ 11.31 B

Total Value

jacob martin wiborg rode

Communications Director at NOVO NORDISK

Manager

bidder

Deals

£ 21.89 B

Total Value

christoffer sho togo

Investor Relations Manager at NOVO NORDISK

Manager

bidder

Deals

£ 10.43 B

Total Value

frederik taylor pitter

Medical Manager at NOVO NORDISK

Manager

bidder

Deals

£ 20.86 B

Total Value

mike doustdar

President and CEO at NOVO NORDISK

Manager

bidder

Deals

£ 10.43 B

Total Value

william h. aaronson

Partner at Davis Polk & Wardwell

Lawyer

bidder

Deals

£ 119.88 B

Total Value

shanu bajaj

Partner at Davis Polk & Wardwell

Lawyer

bidder

Deals

£ 168.27 B

Total Value

sagaar kaul

Counsel at Davis Polk & Wardwell

Lawyer

bidder

Deals

£ 26.66 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy